Fresh From $750M Settlement, Medinol To Pursue Further Royalties From Boston Scientific

Law360, New York (September 27, 2005, 12:00 AM EDT) -- Israeli medical device maker Medinol, fresh from winning a $750 million settlement from Boston Scientific Corp. over sales of coronary stents, plans to pursue future royalties on a next-generation stent, according to the company’s counsel.

“We're going to bring a patent infringement case. . . . It's going to cover the Liberte and other products of theirs that we say infringe on our intellectual property,” Rory Millson, an attorney with Cravath, Swaine & Moore, told Reuters.

Boston Scientific will launch its Taxus Liberte drug-coated stent in...
To view the full article, register now.